Deploying AI Agents for Pharma and Life Sciences

AI agents are changing how new medicines get discovered, tested, approved, and monitored. Historically, drug development has been structurally slow and selective. New medicines cost over $2 billion on average to develop, R&D pipelines usually last 10-15 years, and then even once the development phase is complete, only about one in ten candidates that reach clinical trials win approval. The data load is just as heavy. A single late-stage program generates terabytes across labs, imaging, genomics, and safety, and one regulatory filing can run to tens of thousands of pages. Agents can help solve some of these bottlenecks.

The difference between earlier stages of pharma AI and agents deployed in the industry today is that earlier stages were able to return predictions, while agents can run an entire workflow. An agent pulls from validated sources, reasons across them, calls the right tools, and hands a draft or a decision to a person who signs off. While earlier applications of AI in pharma may have solved one of those steps, agents fit the document-heavy, multi-step, expert-gated work that occupies discovery, clinical, regulatory, and safety teams.

When it comes to deploying AI agents, the industry's largest challenge remains the governance layer. In production, every tool call lands on a system governed by 21 CFR Part 11, GxP, the EU AI Act, or GDPR, and agents must be able to hold up against relevant regulatory inspections. Given those strict parameters and evidentiary requirements, the real question is not what agents can do in life sciences. It is where to start, where it gets hard, and what changes when the actor on your systems is an agent instead of a person.

Start with the work that is already document-bound

The safest first wins are problems where the inputs are validated sources, the outputs are documents, and each workflow requires human approval for each step. In that setup an agent compresses the assembly and the review without touching judgment, and any mistakes are caught in human review before they can reach a regulated record.

Regulatory writing is the clearest case. An agent drafts Common Technical Document sections from structured inputs and checks those drafts against current FDA, EMA, and ICH guidance. It then assembles responses to agency questions straight from the dossier, and absorbs the recurring grind of periodic safety reports, annual reports, and variation filings. The work is high-volume and rule-bound. That is what agents do well, and it is where a reviewer can still catch a problem in time.

Medical affairs and literature monitoring work the same way. An agent searches PubMed, Embase, and the preprint servers, extracts structured findings, and builds evidence summaries and gap analyses. It drafts medical information replies to clinician questions. The payoff is a living review that updates as evidence lands.

Pharmacovigilance case intake is a third application. These workflows are primed for autonomous processes because the volume is brutal, the rules are explicit, and a safety physician still owns the call. An agent ingests adverse event reports from MedWatch, EudraVigilance, the literature, and trial data. It extracts the patient details, suspect product, event, seriousness, and causality. It codes the event in MedDRA and checks expectedness against the Reference Safety Information. Through an agentic workflow, Individual Case Safety Reports and aggregate reports like the PSUR shift from a deadline scramble to a steady process.

Where agent deployment for life sciences gets harder (but also more lucrative)

The higher-value work also carries higher risk. For some of the workflows where agents would be most useful, they would also encounter the most regulatory bottlenecks and the heaviest requirements around traceability.

One such workflow is drug discovery. An agent searches genomic, proteomic, and structural databases for targets, screens virtual compound libraries through docking and structure-activity models, predicts ADMET properties, and ranks the survivors. The upside is large, but the reasoning behind a shortlist is hard to audit, so a discovery agent informs scientific direction rather than setting it.

Another is clinical operations, where the exposure shifts to patient data and protocol integrity. An agent forecasts enrollment, matches cohorts from health records and registries to protocol criteria, and watches incoming trial data for safety signals and deviations. Each of those steps touches regulated data and the integrity of a study that a regulator will later read line by line.

A third is manufacturing and quality, which sit one step from a release decision. Under GMP, an agent triages batch records, flags deviations, and drafts the CAPA documentation that follows. It clears the manual work, but a quality professional still makes the call.

The three are hard for the same reason. In each one, the agent's output feeds a decision a regulator can later challenge, which pulls in the full regulatory stack. GxP work requires computerized-system validation under GAMP 5, with installation, operational, and performance qualification, plus change control and periodic review. The EU AI Act classifies clinical decision-support and diagnostic AI as high-risk where it qualifies as a medical device, which adds requirements for human oversight, transparency, and robustness testing. ICH E6(R3) and E8(R1) set a risk-proportionate, quality-by-design standard, and trial AI has to fit inside it and be written into the quality system. Underneath all of it, regulators want a regulated decision to be explainable, and that single expectation is the strongest argument for keeping agents on assembly while humans own the decision.

What changes when the user is an agent

Identity and data-loss tools were built for a human clicking buttons, and an agent breaks three of the assumptions underneath them. Working through those three breaks is most of what a compliant deployment involves.

The first is attribution. ALCOA+ and 21 CFR Part 11 assume every action traces back to an authorized identity, but an autonomous actor that hands work to other agents does not fit a static role grant. It needs its own identity, authenticated through the same provider as the human behind it, with permissions that match that person and get checked on every request.

The second is the audit record. A click used to be enough to log, but an AI action is not. An inspector needs to reconstruct who started the request, what sources it touched, which model version produced the output, what the output said, and whether a human approved it, with timestamps the whole way.

The third is the threat model. The attacks that matter are MCP-specific, and they often span several calls, which is why prompt-level guardrails miss them. Tool poisoning, tool shadowing, command injection, and rug pulls slip past, and so does the slow exfiltration that no single call reveals. That gap is worse in life sciences, where the data being pieced together is identifiable patient data and unpublished IP. Shadow MCP servers wired straight to production systems are common, and a meaningful share of the servers in the wild are malicious. The job is to catch all of this at the tool-call level before it reaches a regulated system.

How Runlayer governs agents in regulated environments

This is the problem Runlayer is built to solve, and its answer lines up with the same three breaks.

• Identity and attribution: Runlayer gives each agent its own managed identity through Agent Accounts and On-Behalf-Of token exchange across Okta, Entra, and Google Workspace. Per-agent policies sync automatically as connectors are linked or unlinked, so the agent inherits the human's permissions and gets checked on every request.
• Audit trail: Runlayer logs every tool call, policy decision, approval, OAuth event, and agent run with OpenTelemetry tracing and full session replay. That is the record an inspector asks for, and Gusto, a HIPAA-regulated payroll platform and Runlayer customer, points to it as its essential compliance driver.
• Threat detection and containment: Runlayer Guard runs purpose-built, non-LLM models that score every call in 50 to 100 milliseconds, with the IO Guard Model reaching 99% ROC-AUC. The scale of the problem shows up quickly. Gusto found 800 shadow MCP servers on the first day it turned on Runlayer Watch. And with regards to data residency requirements, Runlayer runs single-tenant in your VPC with no co-mingling, TLS 1.3 in transit, and AES-256 at rest.

To see how this plays out in a regulated setting, consider a pharmacovigilance agent asked to draft a narrative for an incoming case. Instead of staying within the case file, it issues a series of reads across separate patient records, each one looking routine on its own. Stitched together, they rebuild an identifiable cohort. Every individual call clears a keyword filter, but the pattern across them is the attack. Runlayer's semantic alignment detection, covered by US Provisional Patent 63/984,897, knows what the agent was asked to do and flags calls that drift away from it, including exactly this kind of aggregation. Because it works at the tool-call level, it catches what prompt-level filters cannot see.

In addition to Gusto, many other HIPAA-regulated companies already trust Runlayer as their enterprise AI platform. Jane App, a health software company with 800+ employees, reached full company-wide adoption of Runlayer in two weeks. To keep PHI in place, the team used Runlayer's policy engine to fence off specific Google Drive folders while still opening Gmail, Calendar, and Drive to Claude. Additionally, no connector runs at Jane unless it runs through Runlayer, and Watch enforces that at the endpoint through existing MDM software like Jamf and Intune. Chief AI Adoption Officer Mark Hazlett put it plainly. "We needed to accelerate the rate of AI adoption at Jane, without compromising security in the process. Runlayer delivered in full."